Overview
Tenax Therapeutics reports Q3 net loss of $15.8 mln, up from $4.0 mln last year
Operating expenses for Q3 rise significantly due to increased R&D and personnel costs
Result Drivers
R&D EXPENSES - Increased R&D costs due to ongoing Phase 3 LEVEL study and LEVEL-2 study preparations
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$15.80 mln
Q3 Operating Expenses
$16.81 mln
Q3 Operating Income
-$16.81 mln
Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Tenax Therapeutics Inc is $20.00, about 64.8% above its November 11 closing price of $7.04
Press Release: ID:nGNX41FxpJ
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
